Warning: file_put_contents(C:\wwwroot\www.prositsole.com\data\models\en_content_news.tableinfo.cache.php) [function.file-put-contents]: failed to open stream: Permission denied in C:\wwwroot\www.prositsole.com\core\library\Model.class.php on line 146
Prosit Sole innitiated a First-in-humans study of the safety, tolerability, and pharmacokinetics of PSP001, a new type of immunomodulator form family Interfon Lambda - PSP001 - A First-in-disease human PEGIFN-λ Chimera - Prosit Sole Biotechnology

PSP001 - A First-in-disease human PEGIFN-λ Chimera

Prosit Sole innitiated a First-in-humans study of the safety, tolerability, and pharmacokinetics of PSP001, a new type of immunomodulator form family Interfon Lambda

Date:2024-07-04 17:32:35 | Visits：

First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.

Prev:Feb. 03, 2021, FDA approved IND filing and Sigle Ascending Dose trial may Proceed
Next:

Contact

Beijing Headquarter:

Add: No. 403 Building 6, No. 18 court Kechuang 13th Street, BDA, Beijing, P. R. China. 100176

Manufacturing Facility & Laboratory:

Building No. 3, Peptide Valley, GuAn, Hebei, China

US Clinical Center:

Seattle, WA, USA